MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Phase 2
Conditions
Refractory B Acute Lymphoblastic Leukaemia
Relapsed B Acute Lymphoblastic Leukaemia
Interventions
Biological: CD19 CAR-T CELLS
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2019-05-03
Last Posted Date
2019-05-06
Lead Sponsor
National University of Malaysia
Target Recruit Count
10
Registration Number
NCT03937544
Locations
🇲🇾

UKM Medical Centre, Bandar Tun Razak, Kuala Lumpur, Malaysia

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Phase 2
Withdrawn
Conditions
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Unresectable Renal Pelvis Urothelial Carcinoma
Unresectable Ureter Urothelial Carcinoma
Interventions
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Pembrolizumab
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Aldesleukin
First Posted Date
2019-05-02
Last Posted Date
2020-01-02
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT03935347
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

First Posted Date
2019-04-24
Last Posted Date
2022-10-20
Lead Sponsor
Delta-Fly Pharma, Inc.
Target Recruit Count
450
Registration Number
NCT03926624
Locations
🇺🇸

University of California, Irvine, California, United States

🇺🇸

Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States

🇺🇸

The University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 36 locations

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Phase 1
Completed
Conditions
MRD-positive
Acute Lymphoblastic Leukemia
Interventions
Biological: anti-CD19/CD22 CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2019-04-18
Last Posted Date
2023-12-08
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
19
Registration Number
NCT03919526
Locations
🇨🇳

Shanghai General Hospital, Shanghai, Shanghai, China

Compassionate Use Re-Infusion of ATLCAR.CD30

Conditions
Hodgkin Lymphoma, Adult
First Posted Date
2019-04-16
Last Posted Date
2021-12-03
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Registration Number
NCT03914885
Locations
🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Phase 1
Terminated
Conditions
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Interventions
Drug: KITE-439
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
First Posted Date
2019-04-11
Last Posted Date
2023-12-26
Lead Sponsor
Gilead Sciences
Target Recruit Count
8
Registration Number
NCT03912831
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1
Active, not recruiting
Conditions
Mesothelioma
Mesotheliomas Pleural
Mesothelioma Peritoneum
Cholangiocarcinoma
Non Small Cell Lung Cancer
Mesothelioma, Malignant
Mesothelioma; Pleura
Cholangiocarcinoma Recurrent
Ovarian Cancer
Non Small Cell Lung Cancer Metastatic
Interventions
Biological: gavo-cel
Drug: fludarabine
Drug: cyclophosphamide
Drug: Nivolumab
Drug: Ipilimumab
First Posted Date
2019-04-09
Last Posted Date
2024-03-06
Lead Sponsor
TCR2 Therapeutics
Target Recruit Count
36
Registration Number
NCT03907852
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Duke University, Durham, North Carolina, United States

and more 8 locations

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Phase 1
Completed
Conditions
Hematological Malignancy
Acute Leukemia in Remission
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndromes
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Interventions
Biological: Cord blood stem cells
Drug: Valproic Acid
Drug: Fludarabine
Drug: cytoxan
Drug: Thiotepa
Biological: TBI
First Posted Date
2019-03-22
Last Posted Date
2021-05-24
Lead Sponsor
Alla Keyzner
Target Recruit Count
7
Registration Number
NCT03885947
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

Phase 1
Conditions
POMES Syndrome
Relapsed and Refractory POMES Syndrome
Interventions
Biological: anti-CD19/BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2019-03-18
Last Posted Date
2021-08-06
Lead Sponsor
Hrain Biotechnology Co., Ltd.
Target Recruit Count
10
Registration Number
NCT03879382
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Interventions
Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
First Posted Date
2019-03-13
Last Posted Date
2024-04-29
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
14
Registration Number
NCT03873805
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy